Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $146.2 million.

  • Xeris Biopharma Holdings' Non-Current Assets fell 766.31% to $146.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $602.6 million, marking a year-over-year decrease of 719.66%. This contributed to the annual value of $155.4 million for FY2024, which is 657.7% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Non-Current Assets stood at $146.2 million for Q3 2025, which was down 766.31% from $149.1 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Non-Current Assets ranged from a high of $173.0 million in Q2 2023 and a low of $6.9 million during Q3 2021
  • Moreover, its 5-year median value for Non-Current Assets was $157.7 million (2022), whereas its average is $149.9 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Non-Current Assets surged by 223124.37% in 2021, and later tumbled by 766.31% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Non-Current Assets (Quarter) stood at $161.8 million in 2021, then dropped by 2.51% to $157.7 million in 2022, then grew by 5.47% to $166.3 million in 2023, then fell by 6.58% to $155.4 million in 2024, then decreased by 5.94% to $146.2 million in 2025.
  • Its Non-Current Assets stands at $146.2 million for Q3 2025, versus $149.1 million for Q2 2025 and $152.0 million for Q1 2025.